問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



MacKay Memorial Hospital

Link to Hospital │ Link to Clinical Trial Center

  • 0

    Total Beds

  • 0

    Total Doctors

  • mmhcto@gmail.com
  • Alice Huang
  • 25433535-2851
  • 104Taipei CityJhong ShanNo. 92, Sec. 2, Zhongshan N. Rd., Taipei City 10449, Taiwan

Recruiting Trial

221Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

589Cases

2010-02-01 - 2011-01-31

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Terminated13Sites

2017-05-01 - 2023-10-30

Phase III

Open-Label, Randomized Trial of Nivolumab (BMS-936558) plus Pemetrexed/Platinum or Nivolumab plus Ipilimumab (BMS-734016) vs Pemetrexed plus Platinum in Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) Subjects with Epidermal Growth Factor Receptor (EGFR) Mutation, T790M Negative Who Failed 1L EGFR Tyrosine Kinase Inhibitor Therapy

  • Condition/Disease

    NSCLC

  • Test Drug

    Nivolumab (BMS-936558),Ipilimumab (BMS-734016)

Participate Sites
16Sites

Terminated14Sites

黃煦晴
Taipei Veterans General Hospital

楊政達
Linkou Chang Gung Medical Foundation

Division of Thoracic Medicine

2021-10-21 - 2022-11-15

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
5Sites

Not yet recruiting5Sites

2010-08-01 - 2020-07-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
16Sites

Terminated16Sites

2015-02-25 - 2025-12-31

Phase III

A PHASE III PROSPECTIVE DOUBLE BLIND PLACEBO CONTROLLED RANDOMIZED STUDY OF ADJUVANT MEDI4736 IN COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Condition/Disease

    COMPLETELY RESECTED NON-SMALL CELL LUNG CANCER

  • Test Drug

    MEDI4736

Participate Sites
13Sites

Not yet recruiting2Sites

Recruiting3Sites

Terminated8Sites

2014-03-01 - 2019-01-31

Phase III

A phase III, placebo-controlled, multi-center, randomized, double-blind trial to evaluate the efficacy and safety of K-333 (peretinoin) in patients with complete cure of hepatocellular carcinoma in Asia

  • Condition/Disease

    hepatocellular carcinoma

  • Test Drug

    K-333

Participate Sites
17Sites

Terminated16Sites

Study ended1Sites

鄭隆賓
China Medical University Hospital

2014-05-01 - 2017-12-31

Phase III

A Multi-center, Randomized, Double-Blind, Double-Dummy, parallel, Controlled, Phase III Clinical Trial Evaluating the Efficacy and Safety of Nemonoxacin Malate Sodium Chloride Injection versus Levofloxacin Sodium Chloride Injection in the Treatment of Adult Community-Acquired Pneumonia.

  • Condition/Disease

    Adult Community-Acquired Pneumonia

  • Test Drug

    Nemonoxacin Malate Sodium Chloride

Participate Sites
17Sites

Terminated17Sites

2016-01-01 - 2019-12-31

Phase IV

A Multi-Center, Open-Label, Single-Arm, Phase IV Study to Evaluate the Safety and Clinical Efficacy of Oral Administration with Nemonoxacin in Treating Elderly Patients with Community-Acquired Pneumonia

  • Condition/Disease

    h Community-Acquired Pneumonia

  • Test Drug

    Taigexyn

Participate Sites
9Sites

Terminated9Sites

李岡遠
Taipei Medical University-Shuang Ho Hospital,Ministry of Health and Welfare

Division of Thoracic Medicine

2013-10-01 - 2020-07-31

Phase III

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Pancreatic Cancer

  • Test Drug

    NC-6004

Participate Sites
17Sites

Terminated17Sites

蘇五洲
National Taiwan University Hospital

Division of Hematology & Oncology

2006-08-01 - 2009-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

1 55 56 57 58 59
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB